Navigation Links
Savient Submits Biologics License Application (BLA) for pegloticase
Date:10/31/2008

EAST BRUNSWICK, N.J., Oct. 31 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced the submission of its BLA to the U.S. Food and Drug Administration (FDA) seeking approval to market pegloticase in the United States along with its request for a priority review. Savient's filing includes data from both the six-month placebo controlled Phase 3 pivotal trials, as well as data from the Open Label Extension (OLE) study. The data set includes 101 patients with at least twelve months continuous treatment.

"Filing the BLA for pegloticase is a major milestone for Savient," said Christopher Clement, President and Chief Executive Officer. "This filing reflects our commitment to changing the paradigm of therapy available to the treatment-failure gout population and brings us one step closer to commercializing this drug and offering a solution to patients who suffer from this debilitating disease."

The two replicate, six-month, Phase 3 clinical trials for pegloticase were performed under the auspices of a Special Protocol Assessment (SPA) and pegloticase was granted Orphan Drug designation by the FDA. The OLE study was established to allow patients who completed the Phase 3 program the opportunity to continue to receive pegloticase for an extended period of time.

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals is a biopharmaceutical company engaged in developing and distributing pharmaceutical products that target unmet medical needs in both niche and broader markets. The company's product development candidate, pegloticase for treatment-failure gout, has reported positive Phase 1, 2 and 3 clinical data. Patient dosing in the Phase 3 clinical studies began in June 2006; patient
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
2. Savients Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
3. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
6. AMDL Submits Data to FDA for Clearance to Market Its DR-70(R) Diagnostic Test to Monitor Colorectal Cancer Patients
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
9. Exelixis Submits XL139 Diligence Report to Bristol-Myers Squibb
10. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
11. MedImmune Submits Biologics License Application to FDA for Motavizumab

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...ntario, Nov. 6 Helix Bio...) today announced that John Docherty, president an...n Curhan Ford,s 6th annual Investor Summit on Nove...ew York City. Mr. Docherty will provide an overvi...ograms L-DOS47 and Topical Interferon Alpha-2b. T...
(Date:11/6/2009)...Nov. 6 /PRNewswire-FirstCall/ - Oncolytics Biotech..."Company") today announced updated results from a ...nts with sarcomas metastatic to the lung in a post...ue Oncology Society Meeting held in Miami Beach, F...ntation, entitled "A Phase II Study of Intravenous...
(Date:11/5/2009)...N, Colo., Nov. 5 The endangered bl...e western U.S. This rare carnivore feeds on prair...o plague and often entire population die-offs in t...(FWS) has implemented a ferret breeding program an... their formerly native habitat. Unfortunately, pl...
(Date:11/5/2009)...b., Nov. 5 Transgenomic,...inancial results for the quarter ended September 3...nted in the tables that follow. ,, Third Quart...$366,000 or $0.01 per share for the third quarter ...0.01 per share for the third quarter of 2008. ,...
Breaking Biology Technology:Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 2Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 3Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3Colorado Companies Team Up With U.S. Fish & Wildlife Service to Protect Black-Footed Ferret 2Transgenomic, Inc. Reports Third Quarter 2009 Results 2Transgenomic, Inc. Reports Third Quarter 2009 Results 3Transgenomic, Inc. Reports Third Quarter 2009 Results 4Transgenomic, Inc. Reports Third Quarter 2009 Results 5Transgenomic, Inc. Reports Third Quarter 2009 Results 6Transgenomic, Inc. Reports Third Quarter 2009 Results 7
...ent of Accurate Blood Test for Common Genetic Diso...., Jan. 27 Artemis Health Inc., a privately-held ...ve prenatal diagnostic tests, today announced that...from Stanford University to develop cell-free fe...ing research from the lab of Stephen Quake, Ph.D.,...
...wswire-Asia/ -- Pharmaxis Ltd (AXS: PXS,Nasdaq: ...port to Shareholders,on the afternoon of Wednesday... an investor teleconference the following morning ...s. , The teleconference will be on Thursday, 2...nuary at 4:30pm U.S. East Coast, 1:30pm U.S. West ...
...tics (NYSE Alternext US: CXM) today reported that ...any,s Board of Directors. The resignation reduces..."We thank Dr. Simon for his service to the Board a...ed Christopher J. Reinhard, Chairman and Chief Exe...: http://www.newscom.com/cgi-bin/prnh/20051018/CA...
Other Biology Technology:Artemis Health Licenses Prenatal Cell-Free DNA Analysis Technology from Stanford University 2Artemis Health Licenses Prenatal Cell-Free DNA Analysis Technology from Stanford University 3Cardium Announces Retirement of Director 2Cardium Announces Retirement of Director 3Cardium Announces Retirement of Director 4
(Date:11/4/2009)..., Nov. 4 GenVault Corporation (Car...., Ph.D., has joined its Board of Directors. Dr. ...Salk Institute, is an acclaimed physician-scientis...k Institute, Dr. Brody served as president of The ...ational Academy of Engineering and the Institute o...
(Date:11/3/2009)...be the ultimate loner of the ocean, cruising thous...searchers has discovered that the sharks have main... over tens of thousands of years the white sharks ...hemselves into a population genetically distinct f...ks are a large, highly mobile species," said Salva...
(Date:11/3/2009)...YETTE, Ind. - Chief executives in 35 of the top Fo...es their "ideal salaries" in 2008, according to a ...due University researcher to determine fair CEO co... and corporate governance issues of the day is how...nkat Venkatasubramanian, a professor of chemical e...
Breaking Biology News(10 mins):Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 2Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 3Tags reveal white sharks have neighborhoods in the north Pacific, say Stanford researchers 2Tags reveal white sharks have neighborhoods in the north Pacific, say Stanford researchers 3Tags reveal white sharks have neighborhoods in the north Pacific, say Stanford researchers 4New theory on fairness in economics targets CEO pay 2New theory on fairness in economics targets CEO pay 3New theory on fairness in economics targets CEO pay 4Allied Worlds Susan Chmieleski to Speak at American Society for Healthcare Risk Management 28ASHRM 29 Annual Conference and Exhibition 59740 1Allied Worlds Susan Chmieleski to Speak at American Society for Healthcare Risk Management 28ASHRM 29 Annual Conference and Exhibition 59740 2Allied Worlds Susan Chmieleski to Speak at American Society for Healthcare Risk Management 28ASHRM 29 Annual Conference and Exhibition 59740 3Encorium Group Inc Completes 241 6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement 3B Ends Discussions to Sell En 14524 1Encorium Group Inc Completes 241 6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement 3B Ends Discussions to Sell En 14524 2Encorium Group Inc Completes 241 6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement 3B Ends Discussions to Sell En 14524 3Encorium Group Inc Completes 241 6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement 3B Ends Discussions to Sell En 14524 4Encorium Group Inc Completes 241 6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement 3B Ends Discussions to Sell En 14524 5Hologic Expands Healthcare Investment in Asia 5563 1Hologic Expands Healthcare Investment in Asia 5563 2Hologic Expands Healthcare Investment in Asia 5563 3
... WHITE PLAINS, NY Babies born preterm were more t... full-term infants, according to a new analysis of...e this week in the Springer journal Maternal and C... before 37 completed weeks gestation, is a growing... Dimes. More than a half million babies are born t...
...own as neurons process information by joining into...her across junctions called synapses. But neurons ...Josh Huang, Ph.D., in a lot of cases, they connect... Dr. Huang, a professor at Cold Spring Harbor Lab...olecules guiding this highly specific neuronal tar...
...iologists from Austria and Singapore developed a t... between biology and art. In an article recently p...fasebj.org ) and scheduled for the August 2008 pri... able to coator paintviruses with proteins. This b... efficiency of some forms of gene therapy, help tr...
Other Biology News:Analysis of millions of US births shows association between birth defects and preterm birth 2Scientists discover a molecular scaffold that guides connections between brain cells 2Scientists discover a molecular scaffold that guides connections between brain cells 3Scientists 'paint' viruses to track their fate in the body 2
BMP-2 ELISA Kit from R&D Systems
5x MONO-RABBIT POLY C'GATE DILUENT from AbD Serotec
Argarase from BioVision
SAMPLE DILUENTS BUFFER TRIAL PACK from AbD Serotec
Biology Products: